After neoadjuvant radiochemotherapy (RCT) for locally advanced rectal cancer, 15–27% of
the patients experience a pathological complete response (pCR). This observation raises …

Aim Pathological complete response to neoadjuvant chemoradiotherapy is found in 20% of
patients with rectal cancer undergoing long‐course chemoradiotherapy. Some authors have …

The management of rectal cancer has transformed over the last 3 decades and continues to
evolve. Some of these changes parallel progress made with other cancers: refinement of …

BACKGROUND: Neoadjuvant chemoradiation (CRT) therapy may result in significant tumor
regression in patients with rectal cancer. Patients who develop complete tumor regression …

Objective: To prospectively compare the ability of flourodeoxyglucose-positron emission
tomography (FDG-PET) and computed tomography (CT) to identify a pathological complete …

Purpose The purpose of this study was to compare the outcomes of patients treated with
chemoradiotherapy with a complete clinical response followed by either a “watch and wait” …

In patients with advanced rectal cancer, neoadjuvant chemo radiotherapy provides tumor
downstaging and downsizing and complete pathological response in up to 30% of cases …

BACKGROUND AND PURPOSE: AMPK is a metabolic sensor and an upstream inhibitor of
mTOR activity. AMPK is phosphorylated by ionizing radiation (IR) in an ATM dependent …

Rectal cancers extending through the rectal wall, or involving locoregional lymph nodes
(T3/4 or N1/2), have been more difficult to cure. The confines of the bony pelvis and the …

PURPOSE: To compare CT-, MR-and PET-CT based tumor length measurements in rectal
cancer with pathology. PATIENTS AND METHODS: Twenty-six rectal cancer patients …